POS0855 EVOLUTION OF RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE IN PATIENTS TREATED WITH JAK INHIBITORS: A MULTICENTER RETROSPECTIVE STUDY

Background The treatment to adopt when (Interstitial Lung Disease)ILD is detected in Rheumatoid Arthritis (RA) patients has always been a matter of debate. management and RA-ILD challenging because there still little information available on this topic, the main literature comes from observational studies. No clinical trials have dedicated however its consideration increasing guidelines. There relatively limited data use JAKi with RA-associated ILD. Objectives aim multicenter retrospective study was investigate effectiveness safety RA-ILD. Methods We retrospectively analyzed classified RA undergoing 6 Italian tertiary centres April 2018 June 2022. included at least months active therapy one high-resolution chest tomography (HRCT) carried out within 3 before start treatment. HRCT then compared most recent last follow-up appointment. also kept track pulmonary function tests. Results 43 RA-ILD, 23 males (53.48%) median age (interquartile range, IQR) 68.87 (61.46-75.78) treated JAKi. Clinical disease characteristics reported Table 1. 19.1 (11.03–34.43). forced vital capacity remained stable 22/28 (78.57%) patients, improved 3/28 (10.71%) worsened (10.71%). diffusing Capacity for Carbon Monoxide showed similar trend, remaining 18/25 (72%) improving 2/25 (8%) worsening 5/25 (20%). 37/43 (86.05) cases, 4/43 (9.30%) 2 (4.65%) (Figure 1). Conclusion This seems confirm that might be safe therapeutic option References [1]Manfredi, A.; Cassone, G.; Luppi, F.; Atienza-Mateo, B.; Cavazza, Sverzellati, N.; González-Gay, M.A.; Salvarani, C.; Sebastiani, M. Related Interstitial Disease. Expert Rev Clin Immunol 2021, 17 , 485–497, doi:10.1080/1744666X.2021.1905524. [2]Holroyd, C.R.; Seth, R.; Bukhari, M.; Malaviya, Holmes, Curtis, E.; Chan, Yusuf, Litwic, Smolen, S.; et al. British Society Rheumatology Biologic DMARD Safety Guidelines Inflammatory Arthritis. (Oxford ) 2019, 58 e3–e42, doi:10.1093/rheumatology/key208. Patient Treatment Baseline Av Obs. Age, years, (IQR) Male, n (%) (53.48) Disease Duration, 12.66 (7.61) ILD duration, 5.55 (5.13) Follow-up, months, (14.92) factor positivity, 38 (88.37) ACPA 35 (81.40) pattern, UIP 25 (58.14) NSIP 5 (11.62) LIP (4.65) CPFE 1 (2.33) Indeterminate 10 (23.26) DLCO, mean (SD) 27 65.81 (16.92) FVC, 30 88.76 (24.03) Prescribed JAKi, n/%) Baricitinib 28 (65.12) Filgotinib (6.98) Tofacitinib 9 (20.93) Upadacitinib Use Methotrexate 32 (74.41) Leflunomide (6.97) TNFalpha inhibitors 19 (44.19) Rituximab 12 (27.91) Abatacept 16 (38.10) Tocilizumab 13 (30.23) + Methotrexate, (37.21) Glucorticoids n(%) 26 (60.47) Figure Pulmonary Function Tests High-Resolution Computed Tomography evolution. Upper Panel: evolution HRCT, Middle Panel:.Diffusing (DLCO). Lower Forced (FVC). Acknowledgements: NIL. Disclosure Interests None Declared.